This study will determine whether 36 months of daily atorvastatin or rosuvastatin have equivalent effects in reduction of immune activation, inflammation and immune aging, when given as adjunct therapy among patients receiving antiretroviral therapy in an African cohort
This is a randomized, open-label trial
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
320
Similar rate of reduction of immune activation between atorvastatin and rosuvastatin arms (p<o.05)
measured by percentage of HLADR+CD38+T-cells
Time frame: 12 months
Similar rate of change of immune aging markers, between ART-treated adults with and without statin (atorvastatin and rosuvastatin) adjunct therapy arms (P-value<0.05)
Measured by Percentage of CD4+ and CD8+ naive T-cells or percentage of expressing Ki67 T-cells or percentage of low CFSE+T-cells or increase in percentage of CD28-/CD57+ T-cells or percentage of individuals with low host responses to influenza vaccine among HIV-infected adults at ART initiation
Time frame: 36 months
Similar rate of reduction of inflammatory markers, between atorvastatin and rosuvastatin arms (p<0.05)
Measured by levels of IL6 in pg/ml, hsCRP in pg/ml, d-dimers in pg/ml, IFABP in pg/ml, and LPS in pg/ml
Time frame: 36 months
Biological pathways affected by atorvastatin and rosuvastatin
number of genes down-regulated by either atorvastatin or rosuvastatin
Time frame: 36 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Age-matched, Healthy HIV-negative